Bydureon (exenatide): Complete Guide 2026
Bydureon (exenatide extended-release) is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes. It is the extended-release formulation of exenatide, originally marketed as Byetta (twice-daily). As one of the earlier weekly GLP-1 options, Bydureon offered convenience over the twice-daily version. While it provides meaningful blood sugar control, its weight loss effects (~2-4%) and overall efficacy are more modest compared to newer GLP-1 agents like semaglutide and tirzepatide.
Enzo's Tip
Fun fact: Bydureon's active ingredient was inspired by Gila monster saliva — nature is wild! Enzo respects any lizard that contributed to medical science. This med has been around for a while and gets the job done for blood sugar control. One shot a week keeps the sugar in check! 🦎🐱
Track your Bydureon journey with Enzo
Dose tracking, side effect logging, and a cute cat cheering you on. Free to download.
Quick Facts
| Generic Name | exenatide |
| Manufacturer | AstraZeneca |
| Type | Injectable pen |
| Frequency | Once weekly |
| Primary Indication | Type 2 diabetes |
Bydureon Guides
Enzo reminds you when your next Bydureon dose is due
Dose tracking, side effect logging, and a cute cat cheering you on. Free to download.
Frequently Asked Questions
The guide your doctor doesn't have time to give you
Your complete Bydureon playbook: week-by-week guide, what to eat when nothing sounds good, and how to manage every side effect. Free.
No spam. Unsubscribe anytime.
Medical Disclaimer: Enzo is a tracking companion, not a doctor. Always consult your healthcare provider before starting, stopping, or changing any medication. The information on this page is for educational purposes only and should not be considered medical advice. Individual results may vary.